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Abstract
Background—Cancers in the proximal colon, distal colon, and rectum are frequently studied
together; however, there are biological differences in cancers across these sites, particularly in the
prevalence of microsatellite instability.
Objective—We assessed differences in survival by colon or rectal cancer site, considering the
contribution of microsatellite instability to such differences.
Design—This is a population-based prospective cohort study for cancer survival.
Settings—This study was conducted within the Colon Cancer Family Registry, an international
consortium. Participants were identified from population-based cancer registries in the United
States, Canada, and Australia.
Patients—Information on tumor site, microsatellite instability, and survival after diagnosis was
available for 3284 men and women diagnosed with incident invasive colon or rectal cancer
between 1997–2002, with ages at diagnosis ranging from 18–74.
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Main Outcome Measures—Cox regression was used to calculate hazard ratios for the
association between all-cause mortality and tumor location, overall and by microsatellite
instability status.
Results—Distal colon (hazard ratio=0.59, 95% confidence interval: 0.49–0.71) and rectal
cancers (hazard ratio=0.68, 95% confidence interval: 0.57–0.81) were associated with lower
mortality than proximal colon cancer overall. Compared specifically to cases with proximal colon
cancer exhibiting no/low microsatellite instability, cases with distal colon and rectal cancers
experienced lower mortality, regardless of microsatellite instability status; cases with proximal
colon cancer exhibiting high microsatellite instability had the lowest mortality.
Limitations—Study limitations include the absence of stage at diagnosis and cause of death
information for all but a subset of study participants. Some case groups defined jointly by tumor
site and microsatellite instability status are subject to small numbers.
Conclusion—Proximal colon cancer survival differs from survival for distal colon and rectal
cancer in a manner apparently dependent on microsatellite instability status. These findings
support the premise that proximal colon, distal colon, and rectal cancers are clinicopathologically
distinct.
Keywords
Colorectal cancer; Colon cancer; Rectal cancer; Survival; Microsatellite instability
INTRODUCTION
Cancers arising in sites from the proximal to distal portions of the colon are frequently
studied in combination with each other (i.e., colon cancer), and in combination with cancers
arising in the rectum (i.e., colorectal cancer). Increasing evidence, however, indicates that
risk factors1–5 and molecular profiles6–9 of cancers may differ across these sites. For
example, family history is more strongly associated with risk of proximal colon cancer than
rectal cancer,1 and alcohol consumption is more strongly associated with risk of rectal
cancer than colon cancer. 4 Cancers in the proximal colon are more likely than cancers in the
distal colon and rectum to be diagnosed in women,10,11 to exhibit microsatellite instability
(MSI),7–9,12 and to be diagnosed at a later age.7,10–12
Recent studies suggest that differences in biological characteristics and risk factors across
cancer site within the colon and rectum may translate to differences in survival. In
particular, proximal colon cancer has been associated with poorer survival than distal colon
cancer,10,11,13 but there appears to be little difference in survival for cancers arising in the
distal colon versus rectum.10 This finding is contrary to observations that proximal colon
cancers are more likely to exhibit high MSI (MSI-H) and that MSI-H tumors are, overall,
associated with a more favorable prognosis than tumors exhibiting low or no MSI (MSS/
MSI-L).14 Two recent studies have suggested that finer distinctions in tumor localization
(i.e., subsite within the proximal colon, distal colon, or rectum) are informative of
survival,10,13 although these studies have not evaluated the contribution of MSI status to
survival differences.
Using data from the Colon Cancer Family Registry, we evaluated differences in all-cause
mortality after colon or rectal cancer diagnosis according to tumor site, both overall and by
MSI status.
Phipps et al. Page 2















The study population included men and women diagnosed with incident invasive primary
colon or rectal cancer who were enrolled in the Colon Cancer Family Registry (C-CFR). The
C-CFR is an international resource representing a collaboration between six study centers in
Canada, the United States, and Australia. Recruitment protocols and eligibility criteria have
been described in detail elsewhere.15 The present analysis was restricted to cases identified
from population-based cancer registries and enrolled through four sites (Fred Hutchinson
Cancer Research Center, Seattle, Washington, USA; Mayo Clinic, Rochester, Minnesota,
USA; Cancer Care Ontario, Toronto, Ontario, Canada; University of Melbourne, Melbourne,
Victoria, Australia). Eligible cases were diagnosed between January 1997 and June 2002,
with ages at diagnosis ranging from 18 to 74 years (N=4073). A small number of cases were
diagnosed with synchronous tumors at different sites (N=36 cases with 2 tumors and N=3
cases with 3 tumors); those cases were excluded from the present analysis. Cases completed
risk factor surveys within five years of diagnosis including information regarding: family
history, demographic and anthropometric factors, medical history, smoking history, and use
of nonsteroidal anti-inflammatory drugs (NSAIDs) (https://cfrisc.georgetown.edu/isc/
dd.questionnaires.do). Most cases were interviewed within two years of diagnosis (>85%).
Vital Status
Vital status and date of death were determined via passive follow-up by routine linkage to
cancer registries and national death indices. This information was also obtained through
active follow-up with cases and/or relatives at, on average, five-year intervals after study
recruitment.
Tumor Subsite and Microsatellite Instability Assessment
Tumor subsite was determined based on review of pathology records. Proximal colon cancer
was defined as cancer arising in the cecum, ascending colon, hepatic flexure, transverse
colon, or splenic flexure (ICD-O-3 codes C180, C182, C183, C184, and C185);16 cancers in
the descending (C186) or sigmoid colon (C187) were classified as distal colon cancers, and
cancers in the rectosigmoid junction (C199) or rectum (C209) were grouped together as
rectal cancers. Cases with unknown tumor site were excluded from the present analysis
(N=78).
MSI status was evaluated for cases with available tumor tissue (N=3284). MSI was
determined via genetic analysis for most cases (N=2969), based on a 10-marker panel
(BAT25, BAT26, BAT40, MYCL, D5S346, D17S250, ACTC, D18S55, D10S197, and
BAT34C4) using DNA extracted from formalin-fixed paraffin-embedded normal and tumor
tissue as previously described.17,18 Tumors were classified as MSI-H if instability was
observed for ≥30% of markers (N=423), and as MSS/MSI-L if instability was observed for
<30% of markers (N=2546). For other cases (N=315), MSI was approximated based on
immunohistochemistry testing of four markers: hMLH1, hMSH2, hMSH6, and hPMS2.18,19
Cases who exhibited positive staining for all markers were considered MSS/MSI-L
(N=278); cases who were negative on at least one marker were considered MSI-H (N=37).
Thus, the study population included 2824 MSS/MSI-L and 460 MSI-H cases. Cases with
unknown MSI status were excluded (N=630).
Statistical Analysis
We used Cox proportional hazards regression to evaluate the association between tumor
location and all-cause mortality after cancer diagnosis, where the time axis was defined as
days since diagnosis and death was the outcome of interest. In separate analyses, we
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evaluated associations with grouped tumor sites (i.e., proximal colon, distal colon, rectum)
and with individual tumor subsites (e.g., cecum, descending colon, rectosigmoid junction).
For the analysis of grouped tumor sites, we used the most common group (i.e., proximal
colon) as the referent category; for analyses of individual tumor subsites, we used the most
common subsite within the proximal colon (i.e., cecum) as the referent category.
We also conducted analyses jointly stratifying cases by tumor location and MSI status
(MSS/MSI-L, MSI-H). We assessed heterogeneity by MSI status in associations with tumor
site using likelihood ratio tests to compare models distinguishing tumors at each site by MSI
status to models combining tumors by site regardless of MSI status.
Proportional hazards assumptions were verified by testing for a non-zero slope of the scaled
Schoenfeld residuals on ranked failure times.20 Due to a violation of proportional hazards
when evaluating associations across the full duration of study follow-up, follow-up was
truncated at five years postdiagnosis; thus, all cases still alive at five years postdiagnosis
were censored at that time.
Regression models were adjusted for age at diagnosis (10-year strata), year of diagnosis
(1997–1998, 1999, 2000–2002), sex, study site, education level (high school graduate or
less, some college or vocational school, college graduate), and body mass index (<25.0,
25.0–29.9, ≥30.0 kg/m2); analyses not stratified by MSI were adjusted for MSI. We also
evaluated confounding by NSAID use (yes, no), family history of colorectal cancer in first-
degree relatives (yes, no), smoking (never, former, current smoker), history of endoscopic
screening at least two years prior to diagnosis (yes, no), and race (non-Hispanic white,
other); however, these variables did not influence estimates sufficiently to be included in the
final model (<10% change). Because information on stage at diagnosis was not available for
a large proportion of cases (46%, N=1516), we did not adjust for stage in our primary
analyses. We did, however, conduct sensitivity analyses assessing the impact of stage
adjustment in cases with known stage at diagnosis, and conducted sensitivity analyses
adjusting for T-stage and nodal status (i.e., the T and N components of TNM stage) which
were known for a larger proportion of cases (84%, N=2757). Because hereditary
nonpolyposis colorectal cancer (HNPCC) may be associated with a better prognosis than
sporadic disease,21 and because HNPCC is more likely to be MSI-H and proximally-located
than sporadic disease, we also conducted sensitivity analyses excluding cases with germline
mutations in one of four DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2),
which could reflect HNPCC. All analyses were conducted using STATA SE version 11.0
(College Station, Texas).
RESULTS
After a median follow-up of 6.7 years (range: 0.7–14.5 years), approximately 35% of
enrolled cases were no longer alive (N=1144); of those who died, 66% died in the first 5
years after diagnosis (N=754) (Table 1). Compared to cases who were alive at the end of
follow-up or at five years postdiagnosis (whichever came first), cases who died within five
years of diagnosis were more likely to be male (58% versus 51%), more likely to have ever
been a smoker (64% versus 59%), more likely to have poorly differentiated tumors (26%
versus 16%), and less likely to have MSI-H tumors (8% versus 16%) (p-values all <0.05).
Cases with proximal colon cancer accounted for 38% of the study population; distal colon
and rectal cancers accounted for 28% and 34% of cases, respectively (Table 2). The
distribution of cancer subsite was similar for women and men, with the exception that
women had a greater proportion of cancers located in the cecum (18% versus 13%) and a
lower proportion of cancers located in the rectum (20% versus 27%). The distribution of
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tumor site differed by MSI status: 82% of MSI-H tumors were located in the proximal
colon, compared to 31% of MSS/MSI-L tumors. Tumors in individuals with germline
mismatch repair mutations (N=70) were also more likely to be located in the proximal colon
(71% vs. 37% in other cases, not shown).
Overall, cases with distal colon cancer and rectal cancer experienced significantly lower
mortality than cases with proximal colon cancer (Table 3). However, there was evidence of
interaction in this association with tumor site by MSI status (pinteraction=0.04 and 0.15 for
distal colon and rectal cancer, respectively). Compared to cases with MSS/MSI-L proximal
colon cancer, cases with MSI-H cancer had lower mortality regardless of grouped tumor site
(Figure 1); cases with MSS/MSI-L distal colon or MSS/MSI-L rectal cancer also had
significantly lower mortality than cases with MSS/MSI-L proximal colon cancer. Compared
to cases with MSI-H proximal colon cancer, all MSS/MSI-L case groups experienced
significantly higher mortality, regardless of grouped tumor site. Very few MSI-H cases had
distal colon or rectal cancer, but patterns of association for these case groups were the same
as for MSS/MSI-L distal colon and rectal cancer case groups. MSI status was not associated
with all-cause mortality for cases with distal colon or rectal cancer (HR=0.90, 95% CI:
0.44–1.86; HR=0.72, 95% CI: 0.32–1.63, for MSI-H versus MSS/MSI-L in distal colon and
rectal cancer cases, respectively, not shown). Additional adjustment for stage, or for
components of TNM stage, had little effect on point estimates; all statistically significant
findings remained significant with stage adjustment (results not shown). Exclusion of cases
with germline mismatch repair mutations also had no impact on findings.
Based on observed differences in associations with tumor site by MSI status, analyses of all-
cause mortality by individual tumor subsites were stratified by MSI. Among MSS/MSI-L
cases, those with cancer located within the descending colon, sigmoid colon, rectosigmoid
junction, and rectum experienced significantly lower mortality than cases with cecal cancer
(Table 4). There was no difference in associations across individual subsites within the distal
colon (pheterogeneity=0.73) or rectum (pheterogeneity=0.81). Among MSS/MSI-L proximal
colon cancer cases, those with cancer located in the hepatic flexure experienced significantly
lower mortality than individuals with cancer in the cecum (HR=0.50, 95% CI: 0.26–0.95),
but mortality was otherwise similar across proximal colon subsites (pheterogeneity=0.14).
Results were unchanged when adjusting for stage and when excluding cases with germline
mismatch repair mutations (not shown). Small numbers limited analyses by tumor subsite
for MSI-H cases; however, cases with MSI-H sigmoid colon cancer were found to have
significantly higher mortality relative to cases with MSI-H cecal cancer (HR=2.64, 95% CI:
1.00–6.96). When we analyzed the 8 subsites from cecum to rectum as a continuous
variable, there was a significant association between increasing distance from the cecum and
lower mortality (HR=0.93, 95% CI: 0.90–0.95), with evidence of interaction by MSI status
(p=0.009) (not shown).
DISCUSSION
In this cohort of individuals with invasive colon or rectal cancer, we found that those with
tumors in the distal colon and rectum experienced lower all-cause mortality in the five years
after diagnosis relative to individuals with proximal colon cancer. However, comparisons of
mortality by tumor site differed by MSI status: MSS/MSI-L proximal colon cancer was
associated with the poorest prognosis, whereas MSI-H proximal colon cancer was associated
with the best prognosis. We found little difference in these patterns when more finely
evaluating associations across subsites within the proximal colon, distal colon, and rectum.
Certain limitations should be considered in interpreting these findings. In particular,
inclusion in the study population was contingent on surviving long enough after cancer
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diagnosis to be enrolled in the C-CFR. Selection bias is possible if otherwise eligible cases
who died before they could be enrolled differed from included cases with respect to tumor
location or covariates. Additionally, we were unable to evaluate treatment variables as
confounders or effect modifiers since we did not have this information; however, it is
unlikely that treatment or access to treatment differed substantially by tumor location.
Similarly, we did not adjust for stage at diagnosis because this information was not available
for a large fraction of cases; we were also concerned that stage classification and the
assessment of stage components could differ across tumor subsites, in which case, stage
adjustment could create difficulties for interpretation. We did, however, conduct sensitivity
analyses adjusting for components of stage and adjusting for stage in the subset of cases
with known stage and found that any confounding by stage was not responsible for observed
survival differences. Although we had a large study population, some case groups became
small after stratification by MSI status and tumor site. Specifically, as has been reported by
previous studies,7,9,12 we had few cases with MSI-H distal colon cancer or MSI-H rectal
cancer; thus, interpretation of comparisons with these small case groups should be made
cautiously. Last, although the vast majority of cases (75%) were followed beyond five years
postdiagnosis, we truncated follow-up at five years in this analysis to avoid violations of
proportional hazards assumptions. As a result, cases who died more than five years
postdiagnosis were censored before they experienced the study outcome. However, by
truncating follow-up it also became much more likely that cases who died during the period
of analysis died as a result of their disease and not due to some other cause. Although we did
not have cause of death information for most cases, within the subset of cases for whom we
did have cause of death data (41%), approximately 80% of deaths occurring within the first
5 years postdiagnosis were attributable to colon or rectal cancer, compared to only 41% of
deaths occurring more than 5 years postdiagnosis (not shown).
Consistent with our results, most prior studies have suggested that proximal colon cancers
are associated with greater mortality than distal colon7,10,11,13 and rectal cancers.10
Recently, a study from the Swedish Family-Cancer Database demonstrated significantly
greater cause-specific mortality in patients diagnosed with proximal colon cancer relative to
patients with rectal cancer (HR=1.16, 95% CI: 1.07–1.27), but found no difference in
survival between patients with distal colon versus rectal cancer (HR=1.04, 95% CI: 0.95–
1.15).10 In another analysis, Wray et al. found lower all-cause mortality in patients
diagnosed with cancer located in the sigmoid colon than in those with cancer located in the
cecum, ascending colon, or hepatic flexure (HR=0.90, 95% CI: 0.87–0.92).13
Previous observations that proximal colon cancer is associated with poorer survival than
distal colon or rectal cancer7,10,11,13 appear inconsistent with observations that proximal
colon cancers are more likely to be MSI-H,7,9,12 as MSI-H cancers generally have a more
favorable prognosis than MSS/MSI-L cancers.14 We found that the greater mortality
associated with proximal colon tumor location was restricted to MSS/MSI-L proximal colon
cancer, and that the more favorable survival associated with MSI-H status was limited to
proximal colon cancer. Very few prior studies have considered MSI in evaluating survival
differences by tumor site or, conversely, considered tumor site in evaluating associations by
MSI.12,22,23 One study by Jernvall et al. reported that the survival advantage associated with
MSI-H status was limited to patients with proximal colon cancer.22 Another analysis of
patients enrolled in clinical trials demonstrated greater mortality in distal colon cancer
patients relative to patients with proximal colon cancer, and found this association to be
diminished after excluding MSI-H cases.12 These studies support our finding that the
interaction between MSI and tumor location is of critical importance in evaluating survival
differences by MSI status or tumor location. However, given the rarity of the MSI-H
phenotype in distal colon and rectal cancers in these prior studies12,21,23 and in ours, there
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remains a need to better understand the epidemiologic and clinical profile of MSI-H distal
colon and rectal cancers.
It is possible that differences in all-cause mortality by tumor site reflect underlying
differences in tumor aggressiveness or amenability to screening. Consistent with such a
hypothesis, previous studies have found that sigmoidoscopy24,25 and colonoscopy26,27 are
associated with lower incidence and mortality for distal but not proximal colon cancer.
Proximal colon cancers are more likely to be diagnosed as interval cancers,28,29 which could
imply a more rapid pattern of tumor progression, and are also more likely to be BRAF-
mutated and to exhibit a CpG island methylator phenotype (CIMP);9 these characteristics,
when observed in combination with MSS/MSI-L status, have been associated with poorer
prognosis.30,31 We did not have information on BRAF-mutation or CIMP status, but found
that cancers at all sites within the proximal colon were more likely to be poorly
differentiated than cancers at sites within the distal colon or rectum (results not shown).
Differences in the distribution of MSI status for proximal colon cancer versus distal colon
and rectal cancer may also be indicative of differences in pathways of tumor development.
Previous studies have hypothesized that MSI-H status reflects a pathway(s) of tumor
development distinct from MSS/MSI-L tumors, as reflected by differences in the prevalence
of certain somatic mutations and epigenetic alterations;32 these differences, in turn, may
have an important impact on survival.
In summary, all-cause mortality after diagnosis of colon or rectal cancer differed
significantly for patients with tumors located in the proximal colon relative to patients with
distal colon or rectal cancer. For individuals with proximal colon cancer, mortality risk
differed significantly according to MSI status. MSS/MSI-L proximal colon cancer was
associated with a greater mortality than MSI-H proximal colon cancer, and was also
associated with greater mortality than MSS/MSI-L or MSI-H distal colon or rectal cancers.
Conversely, MSI-H proximal colon cancers were associated with the most favorable
survival. These findings are consonant with a more aggressive clinicopathology of MSS/
MSI-L tumors located in the proximal colon.
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Kaplan-Meier curves for overall survival after colorectal cancer diagnosis according to MSI
status (solid line = MSS/MSI-L, dashed line = MSI-H) and tumor site (black = proximal
colon, medium gray = distal colon, light gray = rectum)
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TABLE 1






Age at diagnosis, y, mean (SD) 57.5 (10.5) 57.7 (11.1) 0.69
Sex <0.001
   Male 1278 (51) 437 (58)
   Female 1252 (49) 317 (42)
Study site
   Ontario, Canada 781 (31) 218 (28) 0.01
   Melbourne, Victoria, Australia 411 (16) 148 (20)
   Minnesota, USA 292 (12) 62 (8)
   Puget Sound, Washington, USA 1046 (41) 332 (44)
Family history of colon or rectal cancer in first-degree relatives
   No 1935 (76) 594 (79) 0.19
   Yes 595 (24) 160 (21)
Race/ethnicity
   Non-Hispanic white 2288 (91) 671 (90) 0.35
   Other 233 (9) 78 (10)
Education
   ≤High school graduate 1030 (41) 332 (45) 0.14
   Some college/vocational school 782 (31) 231 (31)
   College graduate 695 (28) 182 (24)
   Unknown 23 9
BMI, kg/m2
   <25.0 892 (36) 250 (34) 0.51
   25.0–29.9 997 (40) 301 (40)
   ≥30.0 612 (24) 194 (26)
   Unknown 29 9
Smoking status
   Never smoker 1023 (41) 269 (36) 0.02
   Ever smoker 1496 (59) 481 (64)
   Unknown 11 4
Tumor grade
   Well differentiated 214 (9) 44 (6) <0.001
   Moderately differentiated 1709 (75) 476 (68)
   Poorly differentiated 360 (16) 182 (26)
   Unknown 247 52
MSI status
   MSS/MSI-L 2133 (84) 691 (92) <0.001
   MSI-H 397 (16) 63 (8)
MSI = microsatellite instability; MSS = microsatellite stable; MSI-L = low microsatellite instability; MSI-H = high microsatellite instability.
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a
p values for comparison by vital status are based on a t test of group means (age at diagnosis) or χ2(all other variables).
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Table 4










    Cecum 502 (15) 137 (18) 1.0 (ref) 1.0 (ref)
    Ascending colon 377 (11) 96 (13) 0.90 (0.67–1.21) 1.31 (0.64–2.66)
    Hepatic flexure 85 (3) 16 (2) 0.50 (0.26–0.95) 1.75 (0.65–4.72)
    Transverse colon 202 (6) 51 (7) 0.77 (0.55–1.08) 1.47 (0.58–3.74)
    Splenic flexure 74 (2) 18 (2) 0.78 (0.45–1.35) --d
Distal colon:
    Descending colon 146 (4) 26 (3) 0.46 (0.30–0.72) --d
    Sigmoid colon 787 (24) 155 (21) 0.50 (0.39–0.64) 2.64 (1.00–6.96)
Rectum:
    Rectosigmoid junction 317 (10) 72 (10) 0.59 (0.44–0.80) --d
    Rectum 794 (24) 183 (24) 0.57 (0.45–0.72) --d
a
MSS = microsatellite stable; MSI-L = low microsatellite instability; MSI-H = high microsatellite instability
b
Includes only deaths occurring within the first five years after diagnosis (N=754 of 1144 total deaths over study period, i.e., 66%)
c
Adjusted for age at diagnosis, year of diagnosis, sex, study site, education, and body mass index
d
Estimate based on <5 deaths
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